Central Serous Chorioretinopathy and Micropulse Laser Treatment (NCT06346405) | Clinical Trial Compass
RecruitingNot Applicable
Central Serous Chorioretinopathy and Micropulse Laser Treatment
Italy36 participantsStarted 2023-05-31
Plain-language summary
To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone
Who can participate
Age range18 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosis of central serous chorioretinopathy (CSC) with no response to conservative therapy, consisted in Acetazolamide and Eplerenone after six months.
* Foveal serous retinal detachment for at least 6 months.
* Minimum age of 18 years old at the screening time
* Reading and comprehension skills of informed consent
Exclusion Criteria:
* Previous retinal treatment for CSC, except for Acetazolamide and Eplerenone
* No diffuse retinal epitheliopathy
* Other concomitant ocular diseases, such as age related macular degeneration, diabetic retinopathy, choroidal neovascularization
* Not controlled glaucoma with eyedrops, or advanced glaucoma
* Myopia or hypermetropia greater than 6 diopters
* Opacities of dioptric media
* Low quality of optical coherence tomography (OCT) and OCT-Angiography scans
* Low quality images of Fluorescein angiography and indocyanine green angiography
* No written consensus signed.